Relative to the EUC group, participants in the TeleHCV arm were less likely to report injection drug use at SVR12 (adjusted OR = 0.42, 95% CI 0.20–0.87, p = 0.02) and SVR36 (aOR = 0.48, 95% CI 0.21–1.08, p = 0.08), although the latter comparison did not reach statistical significance.
← all excerpts
Harm Reduction in Peer-Assisted Telemedicine for Hepatitis C: Secondary Outcomes of a Randomized Controlled Trial.
1
—
—